Skip to main content
Livermore
Livermore
ZHEN

DG Capital Management, LLC

SEC CIK
0001512716
Latest filing
Aug 12, 2026

The latest 13F from DG Capital Management, LLC covers Q2 2026 (filed Aug 12, 2026): 20 long positions worth $288.7M. The top 10 holdings make up 80.9% of the portfolio, and the largest is Mercury General Corp (MCY) at 17.8%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
8
Est. +$93.7M
Added
4
Est. +$15.1M
Reduced
5
Est. −$18.8M
Sold out
7
Est. −$56.1M

Top 5 holdings

Share of this quarter's portfolio value

  1. MCYMercury General Corp
    17.8%$51.5MHistory
  2. TLNTalen Energy Corp
    13.6%$39.4MHistory
  3. XEX-Energy, Inc.
    9.6%$27.8MHistory
  4. CBZCBIZ, Inc.
    7.3%$21.2MHistory
  5. Riot Platforms, Inc.767292AB1
    6.6%$19.1M

Share of portfolio

Top 5 holdings and the other 15 positions, by share of portfolio value

  1. MCY17.8%
  2. TLN13.6%
  3. XE9.6%
  4. CBZ7.3%
  5. Riot Platforms, Inc.6.6%
  6. Other 15 positions45.0%

Biggest buys

New and added positions, by estimated amount bought

  1. XEX-Energy, Inc.
    +$27.8MNewHistory
  2. CBZCBIZ, Inc.
    +$21.2MNewHistory
  3. ABVXAbivax S.A.
    +$16.3MNewHistory
  4. BSXBoston Scientific Corp
    +$12.8MNewHistory
  5. BURBurford Capital Ltd
    +$8.82MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. XEX-Energy, Inc.
    +9.62 pp0.0% → 9.6%History
  2. CBZCBIZ, Inc.
    +7.33 pp0.0% → 7.3%History
  3. ABVXAbivax S.A.
    +5.64 pp0.0% → 5.6%History
  4. BSXBoston Scientific Corp
    +4.44 pp0.0% → 4.4%History
  5. BURBurford Capital Ltd
    +3.00 pp0.2% → 3.2%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. Sarepta Therapeutics, Inc.803607AD2
    −$20.5MSold out
  2. CZRCaesars Entertainment, Inc.
    −$12.0MSold outHistory
  3. MCYMercury General Corp
    −$11.9MReducedHistory
  4. iShares Tr464287515
    −$10.4MSold out
  5. ATEXAnterix Inc.
    −$6.42MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. Sarepta Therapeutics, Inc.803607AD2
    −8.88 pp8.9% → 0.0%
  2. CZRCaesars Entertainment, Inc.
    −5.18 pp5.2% → 0.0%History
  3. MCYMercury General Corp
    −4.83 pp22.7% → 17.8%History
  4. iShares Tr464287515
    −4.50 pp4.5% → 0.0%
  5. ATEXAnterix Inc.
    −2.78 pp2.8% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$288.7M
+$57.5M (+24.8%) vs. prior quarter
Positions
20
+1 vs. prior quarter
Top 10 concentration
80.9%
Top 10 as share of value
Turnover
28.8%
Q2 2026, one quarter
Average holding period
3.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $501.1M (Q4 2021)

Q1 2021: $395.3MQ2 2021: $451.7MQ3 2021: $487.9MQ4 2021: $501.1MQ1 2022: $495.2MQ2 2022: $267.8MQ3 2022: $217.0MQ4 2022: $163.5MQ1 2023: $176.7MQ2 2023: $193.0MQ3 2023: $164.0MQ4 2023: $151.7MQ1 2024: $154.5MQ2 2024: $141.9MQ3 2024: $193.0MQ4 2024: $147.1MQ1 2025: $183.6MQ2 2025: $211.9MQ3 2025: $173.0MQ4 2025: $124.4MQ1 2026: $231.2MQ2 2026: $288.7M
Q1 2021Q2 2026
13F filings of DG Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 12, 202620$288.7MMCYTLNXEvs. Q1 2026SEC
Q1 2026May 13, 202619$231.2MMCYTLNSarepta Therapeutics, Inc.vs. Q4 2025SEC
Q4 2025Feb 13, 202614$124.4MMCYSarepta Therapeutics, Inc.ACICvs. Q3 2025SEC
Q3 2025Nov 14, 202513$173.0MMCYBURSarepta Therapeutics, Inc.vs. Q2 2025SEC
Q2 2025Aug 14, 202515$211.9MMCYBURTHCvs. Q1 2025SEC
Q1 2025May 14, 202514$183.6MMCYTLNATEXvs. Q4 2024SEC
Q4 2024Feb 13, 202514$147.1MTLNTHCBURvs. Q3 2024SEC
Q3 2024Nov 13, 202414$193.0MTHCTLNCZRvs. Q2 2024SEC
Q2 2024Aug 14, 202416$141.9MTHCCZREVRIvs. Q1 2024SEC
Q1 2024May 14, 202419$154.5MTHCCZRFENCvs. Q4 2023SEC
Q4 2023Feb 12, 202422$151.7MTHCCZRBURvs. Q3 2023SEC
Q3 2023Nov 14, 202322$164.0MTHCCZRHTZvs. Q2 2023SEC
Q2 2023Aug 11, 202328$193.0MTHCHTZCZRvs. Q1 2023SEC
Q1 2023May 11, 202328$176.7MTHCEVRICZRvs. Q4 2022SEC
Q4 2022Feb 13, 202340$163.5MEVRIInvacare CorpTHCvs. Q3 2022SEC
Q3 2022Nov 14, 202260$217.0MInvacare CorpEVRITHCvs. Q2 2022SEC
Q2 2022Aug 12, 202271$267.8MInvacare CorpEVRITPBvs. Q1 2022SEC
Q1 2022May 11, 2022134$495.2MCYHInvacare CorpEVRIvs. Q4 2021SEC
Q4 2021Feb 14, 2022139$501.1MUTHRCYHInvacare Corpvs. Q3 2021SEC
Q3 2021Nov 12, 2021172$487.9MInvacare CorpEVRIUTHRvs. Q2 2021SEC
Q2 2021Aug 12, 2021193$451.7MInvacare CorpUTHRSUMvs. Q1 2021SEC
Q1 2021May 13, 2021124$395.3MUTHRInvacare CorpExtended Stay Amer Inc–SEC

13D and 13G filings

Companies where DG Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

DG Capital Management, LLC does not currently report owning 5% or more of any company.

Latest filings

29 filings on file made by DG Capital Management, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by DG Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
ATEXAnterix Inc.Nov 12, 20253:52 PM ET13G/A4.00%744.5K shares−1.20 ppfrom 5.20%Below 5%Sep 30, 2025SEC
ATEXAnterix Inc.Aug 14, 202511:57 AM ET13G5.20%975.7K sharesNewJun 30, 2025SEC
FENCFennec Pharmaceuticals Inc.Feb 14, 202512:06 PM ET13G/A4.10%1.11M shares–Below 5%Dec 31, 2024SEC
INSEInspired Entertainment, Inc.Nov 12, 202413G/AOld format–––SEC
FENCFennec Pharmaceuticals Inc.Nov 12, 202413G/AOld format–––SEC
IVCInvacare Holdings CorpOct 30, 202413D/AOld format–––SEC
FENCFennec Pharmaceuticals Inc.Jun 27, 202413GOld format–New–SEC
IVCInvacare Holdings CorpApr 10, 202413D/AOld format–––SEC
IVCInvacare Holdings CorpMar 15, 202413D/AOld format–––SEC
IVCInvacare Holdings CorpFeb 15, 202413D/AOld format–––SEC
IVCInvacare Holdings CorpFeb 2, 202413D/AOld format–––SEC
INSEInspired Entertainment, Inc.Jan 29, 202413G/AOld format–––SEC
IVCInvacare Holdings CorpSep 11, 202313D/AOld format–––SEC
IVCInvacare Holdings CorpMay 15, 202313DOld format–New–SEC
INSEInspired Entertainment, Inc.Feb 13, 202313G/AOld format–––SEC
BKEPBlueknight Energy Partners, L.P.Jul 15, 202213G/AOld format–––SEC
BKEPBlueknight Energy Partners, L.P.May 25, 202213D/AOld format–––SEC
BKEPBlueknight Energy Partners, L.P.May 6, 202213D/AOld format–––SEC
BKEPBlueknight Energy Partners, L.P.May 2, 202213D/AOld format–––SEC
AWREAware IncFeb 11, 202213G/AOld format–––SEC